Ligand Pharmaceuticals IncNASDAQ:LGND
- LAST PRICE116.5500
- TODAY'S CHANGE (%)4.9900 (4.4729%)
- Bid / Lots106.9000/ 1
- Ask / Lots135.0000/ 2
- Open / Previous Close112.8000 / 111.5600
- Day Range
- 52 Week Range
- Volume83,407
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LGND |
|---|---|---|
| 09:32 ET | 2365 | 113.375 |
| 09:35 ET | 362 | 113.06 |
| 09:37 ET | 911 | 112.16 |
| 10:09 ET | 100 | 112.125 |
| 10:38 ET | 100 | 113.475 |
| 10:44 ET | 250 | 114.015 |
| 11:07 ET | 100 | 115.165 |
| 11:14 ET | 100 | 115.74 |
| 11:16 ET | 100 | 116.759 |
| 11:21 ET | 100 | 116.76 |
| 11:36 ET | 100 | 117.16 |
| 11:41 ET | 400 | 116.98 |
| 11:59 ET | 200 | 117.39 |
| 12:01 ET | 100 | 117.465 |
| 12:08 ET | 100 | 117.17 |
| 12:28 ET | 100 | 117.76 |
| 12:30 ET | 100 | 117.99 |
| 12:32 ET | 1034 | 117.935 |
| 12:33 ET | 400 | 117.89 |
| 12:42 ET | 300 | 117.565 |
| 12:46 ET | 493 | 117.29 |
| 12:51 ET | 100 | 117.09 |
| 01:08 ET | 100 | 116.64 |
| 01:09 ET | 400 | 117 |
| 01:15 ET | 100 | 117.17 |
| 01:18 ET | 200 | 116.95 |
| 01:20 ET | 121 | 117.36 |
| 01:22 ET | 300 | 117.62 |
| 01:31 ET | 100 | 117.91 |
| 01:33 ET | 604 | 117.46 |
| 01:38 ET | 100 | 117.79 |
| 01:44 ET | 167 | 117.5501 |
| 01:49 ET | 200 | 117.53 |
| 01:54 ET | 200 | 117.32 |
| 01:58 ET | 100 | 117.215 |
| 02:00 ET | 100 | 117.2 |
| 02:07 ET | 191 | 117.6488 |
| 02:20 ET | 100 | 117.08 |
| 02:23 ET | 548 | 116.8266 |
| 02:25 ET | 1587 | 116.82 |
| 02:30 ET | 1534 | 116.45 |
| 02:50 ET | 163 | 116.56 |
| 02:54 ET | 200 | 116.46 |
| 02:56 ET | 125 | 116.2154 |
| 03:08 ET | 400 | 116.64 |
| 03:28 ET | 100 | 116.75 |
| 03:30 ET | 400 | 116.53 |
| 03:37 ET | 100 | 116.705 |
| 03:39 ET | 313 | 116.635 |
| 03:42 ET | 100 | 116.77 |
| 03:51 ET | 517 | 116.38 |
| 03:55 ET | 1098 | 117.03 |
| 03:57 ET | 636 | 116.52 |
| 04:00 ET | 17757 | 116.55 |
Nov 14, 2024
Ligand to Present at Stifel 2024 Healthcare Conference, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
DJ Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital, from 9:38AM ET on Tuesday Nov 12, 2024 by Dow Jones
9:38AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
DJ Ligand Pharmaceuticals Is Maintained at Buy by Benchmark, from 2:54PM ET on Friday Nov 08, 2024 by Dow Jones
2:54PM ET on Friday Nov 08, 2024 by Dow JonesDJ Ligand Pharmaceuticals Is Maintained at Overweight by Barclays, from 1:20PM ET on Friday Nov 08, 2024 by Dow Jones
1:20PM ET on Friday Nov 08, 2024 by Dow JonesDJ Ligand Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 11:26AM ET on Friday Nov 08, 2024 by Dow Jones
11:26AM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ligand Pharmaceuticals Inc | 2.1B | 48.0x | -12.71% |
Harrow Inc | 1.5B | -46.6x | --- |
Immunocore Holdings PLC | 1.6B | -33.8x | --- |
Ocular Therapeutix Inc | 1.4B | -6.5x | --- |
Avadel Pharmaceuticals PLC | 1.0B | -14.8x | --- |
Evolus Inc | 799.8M | -14.3x | --- |
Company Information
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Contact Information
- Headquarters
- 3911 Sorrento Valley Blvd, Suite 110SAN DIEGO, CA, United States 92121
- Phone
- 858-550-7500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- John Kozarich
- Chief Executive Officer, Director
- Todd Davis
- Chief Financial Officer
- Octavio Espinoza
- Chief Legal Officer
- Andrew Reardon
- Independent Director
- Jason Aryeh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
|---|---|
Revenue (TTM) | $152.4M |
Shares Outstanding | 18.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $2.43 |
Book Value | $39.92 |
P/E Ratio | 48.0x |
Price/Sales (TTM) | 13.8 |
Price/Cash Flow (TTM) | 26.1x |
Operating Margin | -12.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
